Novacyt : RESULTS OF ANNUAL GENERAL MEETING

RESULTS OF ANNUAL GENERAL MEETING

Paris, France and Cambridge, UK - 29 September 2020- Novacyt (EURONEXT GROWTH: ALNOV;

AIM: NCYT), an international specialist in clinical diagnostics, held today its Ordinary and Extraordinary General Meeting

The results of the AGM are set out in the table below, with the Company pleased to announce that all resolutions proposed to the shareholders were duly passed:

Resolutions

Votes For

Votes Against

Result

Number

%

Number

%

1)

Approval of the parent company

financial statements for the year

18,222,352

99.7890

38,532

0.2110

Adopted

ended 31 December 2019

2)

Approval

of

the

consolidated

18,222,352

99.7890

38,532

0.2110

financial statements for the year

Adopted

ended 31 December 2019

3)

Appropriation of the result for the

18,114,759

99.4131

106,940

0.5869

year ended 31 December 2019

Adopted

4)

Review

of

the

agreements

referred to in Articles L. 225-38et

18,163,387

99.7494

45,638

0.2506

Adopted

seq. of the French Commercial

Code

5)

Discharge

to the

Board

of

18,161,873

99.5460

82,827

0.4540

Adopted

Directors

6)

Authorisation

for

the

18,136,247

99.2048

145,379

0.7952

Company

to

buy

back

its

Adopted

own shares

7) Terms of

office

of

the

18,049,375

98.7764

223,580

1.2236

members

of

the

Board

of

Adopted

Directors

8) Terms of

office

of

the

18,212,985

99.7328

48,802

0.2672

Adopted

Statutory Auditors

9) Amount of remuneration allocated

to members

of

the

Board

of

17,821,689

98.1853

329,384

1.8147

Adopted

Directors for the year ended 31

December 2019

10)Amount

of remuneration

to

be

allocated

to

members

of

the

17,692,884

97.4987

453,914

2.5013

Adopted

Board of Directors from 1 January

2020

11)Powers for formalities

18,201,594

99.7658

42,721

0.2342

Adopted

Page 1 of 4

Resolutions

Votes For

Votes Against

Result

Number

%

Number

%

12)Amendment of Article 19 of the

18,139,274

99.3793

113,300

0.6207

Adopted

Company's Articles of Association

13)Delegation of authority granted to

the Board of Directors for the

purpose of allocating free shares,

16,534,574

90.8993

1,655,423

9.1007

existing or new, for the benefit of

Adopted

employees of the Company and of

related companies and corporate

officers

14)Delegation of authority granted to

the Board of Directors for the

purpose of granting options to

subscribe

for

and/or

purchase

shares of the Company, to

corporate officers and employees

16,178,893

88.7433

2,052,219

11.2567

Adopted

of the Company or of companies

in the group, involving the waiver

by

shareholders

of

their

preferential subscription right

to

shares

issued

following

the

exercise of subscription options

15)Overall limit on delegations

relating

to

free

shares

and

16,658,088

91.4780

1,551,848

8.5220

Adopted

subscription or purchase options

16)Delegation of authority to the

Board of Directors for the purpose

of issuing ordinary shares of the

Company

and/or

transferable

securities

giving

access to

the

15,210,240

83.4688

3,012,420

16.5312

Adopted

share capital of the Company,

with cancellation of shareholders'

preferential subscription rights in

favour of specific categories of

persons

17)Delegation of authority granted to

the Board of Directors for the

purpose of increasing the share

capital by issuing ordinary shares

or

securities

giving

access

to

16,186,881

88.9385

2,013,199

11.0615

ordinary shares to be issued by

Adopted

the Company immediately or in

the future in consideration for

contributions in kind within the

limit of 10% of the share capital,

except in the

case

of

a public

Page 2 of 4

Resolutions		Votes For	Votes Against	Result
	Number	%	Number	%
exchange offer initiated by the
Company
18)Delegation of authority to the
Board of Directors for the purpose
of issuing ordinary shares and/or
transferable	securities	giving	15,263,457	83.8253	2,945,202	16.1747
immediate and/or deferred access	Adopted
to the capital of the Company,
with cancellation of shareholders'
preferential	subscription rights
and public offerings
19)Delegation of authority to the
Board of Directors for the purpose
of issuing ordinary shares of the
Company	and/or	transferable	16,683,635	91.5149	1,546,883	8.4851	Adopted
securities giving access to the
share capital of the Company,
with preferential	subscription
rights
20)Authorisation to the Board of
Directors, in the event of a capital
increase,	with	or	without	15,594,811	85.6974	2,602,713	14.3026
shareholders'	preferential	Adopted
subscription	rights,	to	increase
the number of securities to be
issued
21)Overall ceiling on delegations of	16,793,807	92.3175	1,397,549	7.6825	Adopted
authority
22)Delegation of authority to the
Board of Directors for the purpose
of issuing ordinary shares and/or	16,086,360	88.7152	2,046,221	11.2848
securities giving access to the	Adopted
Company's capital for the benefit
of members of a company savings
plan
23)Powers for formalities		18,177,470	99.7026	54,219	0.2974	Adopted

Number of participating shareholders (by voting form, proxy or present): 2,326 shareholders representing 18,345,785 shares.

- End -

Page 3 of 4

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer [phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking) [phone]

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

[phone]

FTI Consulting (International) Victoria Foster Mitchell / Mary Whittow [phone]

[e-mail]/[e-mail]

FTI Consulting (France) Arnaud de Cheffontaines [phone]

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

Page 4 of 4